Medicine Henry Quentir Medicine Henry Quentir

Qubit Pharmaceuticals, Sorbonne Université and Q-CTRL Predict Where Water Sits in Drug-Target Protein Pockets on IBM Heron Processors at up to 123 Qubits: What Physical Review Research Published

How Qubit Pharmaceuticals and Q-CTRL predicted water sites in drug-target protein pockets on IBM Heron

Quentir Medicine Monitor

Evidence-based insights for quantum medicine.

Researchers from the Paris drug-discovery company Qubit Pharmaceuticals, Sorbonne Université and the quantum software company Q-CTRL have used IBM quantum computers to predict where water molecules settle inside the binding protein pockets of drug targets. Daniele Loco, Kisa Barkemeyer, Andre Carvalho and Jean-Philip Piquemal cast hydration-site prediction as an optimization problem and solved instances of up to 123 binary variables on 156-qubit IBM Heron processors, using protein structures linked to diseases for which the U.S. Food and Drug Administration has approved a drug. Their paper appeared in Physical Review Research in September 2026, and Quantum Computing Report summarized it on 21 November 2026.

The study answers a practical question for medicinal chemists. A candidate drug binds to its target inside a cavity that is already filled with water, and some of those water molecules help the drug hold on while others must be pushed out before it can bind. Computer-aided drug design programs therefore need a map of the stable water positions before they can estimate binding or set up a docking calculation. The authors show that a quantum optimizer can produce that map at small scale, and they estimate how large a quantum computer must become before the method could be useful in routine drug design.

The work extends an earlier study by part of the same group that placed water in two-dimensional slices of a protein pocket on an analog quantum device built from Rydberg atoms. The new paper handles the full three-dimensional pocket on digital hardware, which brings the problem closer to the structures that pharmaceutical modelers use every day.

Read More
Medicine Henry Quentir Medicine Henry Quentir

INmune Bio Becomes Quantum Computing Inc.'s First Pharma Customer on 14 October 2026: What Dirac-3S Will Search for in the XPro Alzheimer's Trial Data

INmune Bio puts XPro trial data on a quantum optimizer

Quentir Medicine Monitor

Evidence-based insights for quantum medicine.

On 14 October 2026 the Alzheimer's drug developer INmune Bio and the photonics company Quantum Computing Inc. (QCi) announced that INmune Bio will use QCi's Dirac-3S quantum optimization machine to look for new diseases in which its anti-inflammatory candidate drug might work. The engagement is a first stage with options for more, and QCi describes it as its first commercial customer in the pharmaceutical and biotechnology market.

The drug is XPro1595, which INmune Bio calls XPro. It is designed to neutralize the soluble form of tumor necrosis factor, a signaling protein that drives inflammation, while leaving the membrane-bound form, which the immune system and nerve cells rely on, largely untouched. INmune Bio has tested it in early Alzheimer's disease in patients whose blood shows signs of inflammation.

According to the joint announcement issued from Boca Raton and Hoboken, the two companies will combine INmune Bio's data from preclinical work and four clinical trials with public biomedical datasets. The aim is to find new indications, meaning diseases driven by the same inflammatory biology XPro targets, and to rank them by their chance of success. INmune Bio's chief executive David Moss said the search would start with rare diseases, where trials can be smaller and faster, and where a qualifying pediatric approval may earn a priority review voucher from the US Food and Drug Administration.

The announcement contains one commitment that deserves more attention than the headline. The companies say they will compare the quantum machine's output with conventional statistical and machine-learning methods and judge which approach suits which part of the analysis. Whether that comparison is published will decide how much the collaboration teaches anyone outside the two companies.

The largest body of patient data INmune Bio brings to the work comes from MINDFuL, a randomized, double-blind, placebo-controlled phase 2 trial registered as NCT05318976 on ClinicalTrials.gov. The registry lists 207 enrolled participants, a start in February 2022 and completion on 12 May 2025. Patients aged 50 to 85 with mild cognitive impairment or mild dementia and raised inflammatory biomarkers received a weekly injection under the skin of XPro1595 at 1.0 mg/kg or a placebo for 24 weeks, at 35 centers in eight countries.

The results, written up by Judith Jaeger, Christopher Barnum and colleagues in a preprint posted to medRxiv on 27 September 2025, are mixed. In the 200 patients of the modified intent-to-treat population, the drug did not beat placebo on the primary endpoint, a composite of six cognitive tests called the Early and Mild Alzheimer's Cognitive Composite (EMACC), with p = 0.672. The authors write plainly that XPro1595 did not meet the primary endpoint in the overall population.

Read More